INSIGHTS ON DRUG DEVELOPMENT
-
Alcami Capabilities Update October 2026: Fill Finish
Discover critical considerations for sterile fill-finish, including manufacturability, scale-up, contamination control, and the path from clinical to commercial supply.
-
Nose To Brain (N2B) Drug Delivery – Benefits And Challenges
Delve into the growing interest in drug delivery methods that target the brain and central nervous system via absorption into the bloodstream, specifically focusing on crossing the blood-brain barrier (BBB).
-
Doubling Up For Speed In Biomanufacturing
Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.
-
Ask Us Anything: Hannah McLachlan on Crystallization In Peptide Development
Hannah McLachlan, Project Scientist IV at Cambrex Edinburgh, on what crystallization screening delivers for peptide therapeutics — more stable material, higher purity, and a molecule clients can store without specialist infrastructure.
-
Improving API Solubility With Mesoporous Silica6/5/2025
Poor solubility of active pharmaceutical ingredients can hinder drug effectiveness. Learn how innovative formulation strategies enhance solubility and bioavailability to improve therapeutic outcomes for challenging drug candidates.
-
AustinPx Site Tour5/2/2025
Take a virtual tour of AustinPx to explore advanced facilities, including KinetiSol™ technology, and discover how we enable scalable, sustainable performance.
-
Flamma Capabilities Update October 2026: Small Molecule Drug Substance11/3/2026
Discover how new approaches to API and peptide development can improve process control, repeatability, efficiency, and manufacturing readiness.
-
The Power Of Derivatization: Simple Solutions To Complex Analytical Problems9/23/2026
Derivatization can improve detection, separation, and quantification, providing a practical solution for challenging analyses while supporting reliable quality control and regulatory compliance.
-
Isolate Bright GFP-Expressing HEK293 Cells For Cell Line Development Workflow11/7/2025
Explore a high-efficiency workflow for isolating and expanding GFP-expressing HEK293 cells that enables stable, bright clones ideal for imaging and tracking to simplify clonal development.
DRUG DEVELOPMENT SOLUTIONS
-
Waters MaxPeak Premier Columns and Solutions dramatically reduce NSA with MaxPeak High Performance Surfaces, innovative technologies designed to reduce analyte loss due to analyte/surface interactions.
-
Nanoform’s proprietary bionanoparticle technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. This can not only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.
-
We have developed an innovative portfolio of affinity chromatography resins to help you solve challenges in the downstream process of next-generation antibody therapeutics. These resins are specifically designed for the purification of engineered monoclonal antibody (mAbs) modalities.
-
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
-
Re-engineer your drug's path into clinical development and accelerate time to Proof-of-Concept. Real-time data guides rapid formulation iterations, minimizing drug substance use and lowering program risk.